Rafarma Pharmaceuticals Inc
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wou… Read more
Market Cap & Net Worth: Rafarma Pharmaceuticals Inc (RAFA)
Rafarma Pharmaceuticals Inc (PINK:RAFA) has a market capitalization of $12.20 Million ($12.20 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #47798 globally and #14735 in its home market, demonstrating a 17.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rafarma Pharmaceuticals Inc's stock price $0.14 by its total outstanding shares 87766999 (87.77 Million).
Rafarma Pharmaceuticals Inc Market Cap History: 2015 to 2025
Rafarma Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows growth from $394.95K to $12.20 Million (35.20% CAGR).
Rafarma Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rafarma Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.84x
Rafarma Pharmaceuticals Inc's market cap is 0.84 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
28.71x
Rafarma Pharmaceuticals Inc's market cap is 28.71 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $35.02 Million | $11.44 Million | $3.05 Million | 3.06x | 11.47x |
| 2020 | $138.67 Million | $74.73 Million | $14.85 Million | 1.86x | 9.34x |
| 2020 | $138.67 Million | $74.73 Million | $14.85 Million | 1.86x | 9.34x |
| 2021 | $73.29 Million | $77.41 Million | $11.57 Million | 0.95x | 6.33x |
| 2021 | $73.29 Million | $77.41 Million | $11.57 Million | 0.95x | 6.33x |
| 2022 | $38.53 Million | $64.31 Million | $4.96 Million | 0.60x | 7.77x |
| 2022 | $38.53 Million | $64.31 Million | $4.96 Million | 0.60x | 7.77x |
| 2023 | $22.91 Million | $10.13 Million | $273.00K | 2.26x | 83.91x |
| 2023 | $22.91 Million | $10.13 Million | $273.00K | 2.26x | 83.91x |
| 2024 | $7.64 Million | $9.08 Million | $266.00K | 0.84x | 28.71x |
Competitor Companies of RAFA by Market Capitalization
Companies near Rafarma Pharmaceuticals Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Rafarma Pharmaceuticals Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Rafarma Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Rafarma Pharmaceuticals Inc's market cap moved from $394.95K to $ 12.20 Million, with a yearly change of 35.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $12.20 Million | +59.77% |
| 2024 | $7.64 Million | -66.67% |
| 2023 | $22.91 Million | -40.55% |
| 2022 | $38.53 Million | -47.43% |
| 2021 | $73.29 Million | -47.15% |
| 2020 | $138.67 Million | +295.99% |
| 2019 | $35.02 Million | +3890.00% |
| 2018 | $877.67K | -32.89% |
| 2017 | $1.31 Million | +198.00% |
| 2016 | $438.83K | +11.11% |
| 2015 | $394.95K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Rafarma Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.20 Million USD |
| MoneyControl | $12.20 Million USD |
| MarketWatch | $12.20 Million USD |
| marketcap.company | $12.20 Million USD |
| Reuters | $12.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.